The UK and US have concluded a major commercial pact that will preserve no duties on British medicine exports going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that tariffs on these crucial goods will remain at zero for a period of three years.
This development follows earlier statements to significantly raise tariffs on branded drug imports, with potential rates mentioned up to 100%.
"This agreement between the Britain strengthens the worldwide climate for new treatments and introduces much-needed equity to American-British drug exports," an announcement noted.
Trade Impact
Medicines represent one of the the United Kingdom's largest goods shipped to the United States, which is easily the largest destination for leading British pharmaceutical firms.
Statistics show that in the 12 months to the end of September, the UK shipped medicines worth billions to the US. This figure made up nearly one-fifth of British export trade in that span.
"This deal secures jobs, increases funding and paves the way for the UK to become a international leader for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The pact includes several key pledges from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to raise total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to control costs will be restricted at 15%. Previously, repayments exceeded twenty percent.
Industry Background
The deal comes amid a ongoing tension between the pharmaceutical industry and the ministers over spending levels and approval rates.
These tensions were exacerbated by claims that American patients were paying a premium for the same drugs than patients in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been delayed or cancelled, while major expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its overall budget over the last ten years.
